- Home
- GTE vs AVTX Comparison
GTE vs AVTX Comparison
Compare GTE & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTE
- AVTX
- Stock Information
- Founded
- GTE 2003
- AVTX 2011
- Country
- GTE Canada
- AVTX United States
- Employees
- GTE N/A
- AVTX N/A
- Industry
- GTE Oil & Gas Production
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- GTE Energy
- AVTX Health Care
- Exchange
- GTE Nasdaq
- AVTX Nasdaq
- Market Cap
- GTE 139.0M
- AVTX 138.8M
- IPO Year
- GTE N/A
- AVTX 2015
- Fundamental
- Price
- GTE $3.85
- AVTX $11.61
- Analyst Decision
- GTE
- AVTX Strong Buy
- Analyst Count
- GTE 0
- AVTX 8
- Target Price
- GTE N/A
- AVTX $31.00
- AVG Volume (30 Days)
- GTE 241.8K
- AVTX 209.9K
- Earning Date
- GTE 11-03-2025
- AVTX 11-06-2025
- Dividend Yield
- GTE N/A
- AVTX N/A
- EPS Growth
- GTE N/A
- AVTX N/A
- EPS
- GTE N/A
- AVTX N/A
- Revenue
- GTE $621,677,000.00
- AVTX $441,000.00
- Revenue This Year
- GTE $5.03
- AVTX N/A
- Revenue Next Year
- GTE N/A
- AVTX N/A
- P/E Ratio
- GTE N/A
- AVTX N/A
- Revenue Growth
- GTE N/A
- AVTX N/A
- 52 Week Low
- GTE $3.34
- AVTX $3.39
- 52 Week High
- GTE $8.19
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- GTE 39.71
- AVTX 72.39
- Support Level
- GTE $3.78
- AVTX $8.65
- Resistance Level
- GTE $4.30
- AVTX $12.41
- Average True Range (ATR)
- GTE 0.17
- AVTX 0.88
- MACD
- GTE 0.01
- AVTX 0.12
- Stochastic Oscillator
- GTE 12.50
- AVTX 80.00
About GTE Gran Tierra Energy Inc.
Gran Tierra Energy Inc is an independent energy company. The company, along with its subsidiaries, is focused on oil and gas exploration and production, with assets in Colombia, Canada, and Ecuador. It produces oil, natural gas, and natural gas liquids. Gran Tierra has assembled a diversified, high-quality asset base that is fully operated in Colombia and Ecuador and partly in Canada. The company operates various blocks in Colombia and Ecuador, spanning three basins. It also has contiguous areas in Alberta, Canada, spanning various gross acres across the Western Canadian Sedimentary Basin. The company's reportable segments are Colombia, Ecuador, Canada, and Other. A majority of its revenue is derived from its operations in Colombia.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).